A pre-legalization Canadian survey of 709 cannabis users finds that roughly 80% of those who call their use “medical” also use recreationally, that fewer than one in four have a doctor’s authorization, and that medical users report significantly higher daily use and psychiatric symptom scores than recreational-only users. However, the cross-sectional design and enriched convenience sample prevent any causal conclusions about whether cannabis drives or alleviates these symptoms.

Clinicians and policymakers often treat “medical” and “recreational” cannabis use as cleanly separable categories, building screening protocols, access rules, and regulatory frameworks around that distinction. This study directly challenges that assumption in a large community sample, revealing that the vast majority of self-identified medical users also use recreationally and that few hold formal authorization. Understanding who medical cannabis users actually are, rather than who we imagine them to be, is essential for designing clinical encounters and policies that match the reality of patient behavior.

As Canada approached federal cannabis legalization in October 2018, Turna and colleagues surveyed a community research registry to characterize how recreational and medical cannabis users differ in their patterns of use, substance-use comorbidity, and psychiatric symptom burden. The study drew from a McMaster University registry that included approximately 35% emerging adults with high-risk drinking, meaning the overall sample carried elevated substance-use risk compared to the general population. Participants completed validated instruments covering cannabis use disorder (CUDIT-R), alcohol (AUDIT), tobacco (FTND), anxiety (GAD-7), depression (PHQ-9), and PTSD symptoms (PCL-5), alongside cannabis-specific use questions.

Among the 709 cannabis users, 61.4% were recreational-only and 38.6% reported some medical use. Medical users used cannabis dramatically more often, with 40.5% reporting daily use compared to just 5.1% of recreational users. Medical users showed significantly higher CUDIT-R scores and probable cannabis use disorder rates (21.9% vs. 10.3%), though a sensitivity analysis removing the frequency item reduced the medical CUD rate to 13.9%. Psychiatric symptom scores were consistently higher in medical users, but adjusted means generally fell below established clinical screening cutoffs, tempering the clinical severity of these statistical differences. Only 23.4% of self-identified medical users had formal health professional authorization. The authors acknowledge the cross-sectional design prevents any causal interpretation and call for longitudinal and population-based studies to determine the direction and clinical significance of these associations.

Medical or Recreational? For Most Cannabis Users, the Answer Is Both

Ask your next cannabis-using patient whether they use it for medical or recreational reasons, and there is a good chance the honest answer is “yes.” A pre-legalization survey of 709 Canadian adults found that 80% of people who called their cannabis use “medical” also used it recreationally, and fewer than one in four had a doctor’s authorization to show for it. This is a well-executed descriptive study that does something genuinely valuable: it refuses to accept the medical-versus-recreational binary at face value and instead maps the messy overlap that most clinicians intuitively recognize but rarely see quantified. The dual-motive group, those who use cannabis for both health-related and recreational purposes, emerges as the largest and most complex subgroup, with the highest rates of daily use, the most psychiatric symptoms, and the greatest likelihood of screening positive for cannabis use disorder. What the paper genuinely contributes is a granular, data-supported portrait of a population that policy documents and clinical guidelines typically pretend does not exist. The regulatory world imagines two clean lanes: the authorized patient and the recreational consumer. This study shows that most real people are driving down the middle.

The central methodological issue is one that the authors acknowledge but that downstream readers may not fully absorb: this is a cross-sectional snapshot from a convenience registry deliberately enriched with high-risk young drinkers, and no amount of covariate adjustment can fix what the sampling frame introduced. Taking a single photograph of people carrying umbrellas on a rainy day tells you umbrellas and rain are associated, but not whether they brought the umbrella because they expected rain or whether they went outside because they had an umbrella. The photo cannot show the sequence. Similarly, this study cannot tell us whether cannabis use preceded, followed, or simply coincided with the psychiatric symptoms it measured. A related concern is the CUDIT-R’s performance in this population. The screening tool includes a frequency-of-use item that naturally scores high in anyone using daily, regardless of whether that daily use is supervised, intentional, and therapeutic. It is a bit like asking a marathon runner whether they exercise every day and then flagging them for an “exercise disorder” because the frequency question scores high, when the daily activity may be purposive and deliberate. When the authors removed the frequency item, the CUD screening rate among medical users dropped meaningfully, from 21.9% to 13.9%, suggesting the instrument may be measuring dose rather than disorder in this population.

What I would say to a patient is straightforward: the fact that you call your cannabis use “medical” does not change what I need to know. What matters is how much you are using, whether it is helping, whether it is causing problems, and what else might be going on that brought you here. To a colleague, I would emphasize that standard psychiatric and substance-use screening should apply to every cannabis-using patient, regardless of the label they attach to their use. And to a policymaker, I would note that regulatory frameworks built on a clean medical-versus-recreational divide may not reflect reality on the ground. Self-defined categories are genuinely meaningful enough to predict different use patterns and comorbidity profiles, but porous enough that they should never substitute for individualized clinical assessment. The label is a starting point, not a conclusion.

This study sits early in the research arc, providing hypothesis-generating descriptive data rather than actionable clinical evidence. It confirms a pattern that epidemiological surveys have hinted at but rarely quantified: self-identified medical cannabis users are not a homogeneous, formally authorized population, and the boundaries between medical and recreational use are far more permeable than either clinical guidelines or regulatory frameworks typically acknowledge. The findings align with emerging data from post-legalization surveys showing persistent overlap between motivations for use, but the pre-legalization timing and enriched sampling context mean the specific prevalence estimates may already be dated.

From a pharmacological and safety standpoint, the eightfold difference in daily use rates between medical and recreational users is clinically significant, as daily cannabis exposure carries implications for tolerance development, withdrawal risk upon cessation, and potential drug interactions with psychiatric medications, particularly CYP-metabolized antidepressants and anxiolytics. The elevated psychiatric symptom burden in medical users also raises the question of whether cannabis is being used as an informal substitute for evidence-based psychiatric treatment. One concrete takeaway: clinicians encountering any patient who reports cannabis use, regardless of how they label it, should systematically screen for cannabis use disorder, concurrent psychiatric symptoms, and the absence of formal medical oversight, treating the self-applied “medical” label as a clinical prompt for deeper inquiry rather than a reassurance.

This is an original cross-sectional survey study using self-report data from a convenience research registry. It occupies the lower tiers of the evidence hierarchy, generating descriptive associations without any capacity for causal inference, temporal ordering, or experimental manipulation. The single most important inference constraint is that the direction of the relationship between cannabis use and psychiatric symptoms cannot be determined: symptoms may precede, follow, or be entirely independent of cannabis use patterns.

These findings are broadly consistent with prior work by Rotermann and Macdonald (2018) documenting rising cannabis use prevalence and mixed motivations among Canadian adults, and with the 2018 Canadian Cannabis Survey, which similarly found that a substantial proportion of cannabis users reported both medical and recreational reasons for use. The present study extends this work by providing validated psychiatric and substance-use instrument data rather than relying solely on survey-level use questions, and by identifying the dual-motive subgroup as a distinct population with the highest use intensity. However, unlike probability-based national surveys, this registry sample’s enrichment with high-risk drinkers limits direct comparison of prevalence estimates. Longitudinal cohort studies tracking psychiatric symptoms before and after cannabis initiation or medical authorization would be needed to test the causal hypotheses this descriptive work generates.

The most consequential analytic choice was retaining the CUDIT-R frequency item in the primary analysis, which mechanically inflates cannabis use disorder screening rates among daily users, a group overwhelmingly represented among medical users. The authors commendably conducted a sensitivity analysis removing this item, which reduced the probable CUD rate from 21.9% to 13.9% among medical users, a meaningful attenuation. Had this modified scoring been the primary analysis, the headline difference in CUD prevalence between groups would have been substantially smaller. Additionally, the absence of any adjustment for chronic pain or physical health conditions is notable. Including these variables as covariates could have meaningfully reduced the apparent psychiatric symptom differences between groups, as chronic pain is both a leading reason for medical cannabis use and a strong independent predictor of elevated anxiety, depression, and trauma symptom scores.

The most likely overinterpretation is the inference that medical cannabis use causes psychiatric symptoms or cannabis use disorder. This study is cross-sectional: it takes a single measurement at one point in time and cannot determine whether psychiatric symptoms preceded, resulted from, or simply co-occurred with cannabis use. It is equally plausible that people with pre-existing anxiety, depression, or trauma symptoms turned to cannabis for relief and then reported both conditions simultaneously. A second common misreading is treating the prevalence estimates as representative of all Canadian cannabis users. The registry was deliberately enriched with high-risk young drinkers, meaning substance-use and potentially psychiatric symptom rates are inflated relative to the general cannabis-using population. Finally, while psychiatric symptom scores were statistically higher in medical users, most adjusted group means fell below established clinical screening thresholds, meaning the differences are real but may not indicate clinically severe psychopathology for the average medical user in this sample.

This study contributes a valuable descriptive portrait showing that the boundary between medical and recreational cannabis use is highly permeable, that dual-motive use is the norm rather than the exception among medical users, and that medical users carry greater but often subclinical psychiatric symptom burdens. It does not establish causation, population-level prevalence, or whether cannabis helps or harms mental health. For clinical practice today, it supports the principle that every cannabis-using patient warrants individualized screening regardless of how they label their use.

Does this study prove that medical cannabis use causes anxiety or depression?

No. This is a cross-sectional survey, meaning it captured a snapshot at one point in time. It found that people who use cannabis medically report more anxiety and depression symptoms, but it cannot determine whether cannabis caused those symptoms, whether the symptoms preceded cannabis use, or whether both simply co-occur. People with existing mental health challenges may be more likely to seek relief through cannabis, which would produce the same statistical pattern without cannabis being the cause.

If most medical users also use recreationally, does that mean medical cannabis is not legitimate?

Not at all. Many medications that provide genuine therapeutic benefit also produce pleasurable effects or are used in contexts beyond their strictly prescribed purpose. The finding that most medical users also enjoy cannabis recreationally tells us that motivations overlap in practice, but it does not invalidate the medical reasons for use. It does, however, suggest that clinicians should not assume “medical” means exclusively therapeutic or formally supervised.

Should I be worried if I use cannabis daily for a medical condition?

Daily use is not inherently dangerous, but it does warrant a conversation with a knowledgeable healthcare provider. This study found that standard screening tools can flag daily medical users as having a “cannabis use disorder” largely because of the frequency of use, not necessarily because of harmful consequences. The important question is whether your use is supervised, whether it is achieving what you intend, and whether you are experiencing any negative effects on your health, relationships, or daily functioning.

Can I trust these numbers as representative of all cannabis users?

The specific prevalence estimates in this study should be interpreted with caution. The research registry from which participants were drawn was intentionally enriched with young adults who had high-risk drinking patterns, which likely inflated the rates of substance use and psychiatric symptoms beyond what would be found in a random sample of the general population. The patterns and group comparisons are informative, but the exact numbers may overestimate the problem.

References

1. Turna J, Balodis I, Munn C, Van Ameringen M, Busse J, MacKillop J. Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users. Comprehensive Psychiatry. 2020. doi:10.1016/j.comppsych.2020.152188
2. Health Canada. Canadian Cannabis Survey 2018. Ottawa: Health Canada; 2018.
3. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap). J Biomed Inform. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
4. Adamson SJ, Kay-Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse: The Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depend. 2010;110(1-2):137-143. doi:10.1016/j.drugalcdep.2010.02.017
5. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT). Addiction. 1993;88(6):791-804. doi:10.1111/j.1360-0443.1993.tb02093.x
6. Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3(3-4):235-241. doi:10.1016/0306-4603(78)90024-2
7. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder. Arch Intern Med. 2006;166(10):1092-1097. doi:10.1001/archinte.166.10.1092
8. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. doi:10.1046/j.1525-1497.2001.016009606.x
9. Weathers FW, Litz BT, Keane TM, et al. The PTSD Checklist for DSM-5 (PCL-5). National Center for PTSD; 2013.
10. Breslau N, Peterson EL, Kessler RC, Schultz LR. Short screening scale for DSM-IV posttraumatic stress disorder. Am J Psychiatry. 1999;156(6):908-911. doi:10.1176/ajp.156.6.908
11. Rotermann M, Macdonald R. Analysis of trends in the prevalence of cannabis use and related metrics in Canada. Health Rep. 2018;29(2):11-22.

Have thoughts on this? Share it:

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care

• Newsletter Signup Form

  Enter your email address to subscribe to our newsletter.
• Email Address*
  example@example.com
• Subscribe
• Should be Empty: